Historically, the decision-making processes regarding the prognosis of patients with prostate cancer and the optimal therapeutic approach have been driven by clinical and pathological variables, such as tumour stage, Gleason score and serum prostate-specific antigen (PSA) levels 1, 2 . However, new insights into the genomic aberrations underlying prostate cancer are rapidly transforming the diagnosis and treatment of patients with this disease, from early detection through to treatment of late-stage tumours. Characterizing the molecular landscape of prostate cancer through 'omics' level analyses has, historically, been technically challenging owing to the small size of the available diagnostic specimens (usually corebiopsy samples), the difficulties in gross identification of tumours at the time of resection (such as procurement of fresh tissue for high-quality nucleic acid isolation) and the difficulties in obtaining highly pure samples of the tumour population, owing to the presence of large amounts of stroma and normal tissue within cancer foci.
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Characterizing the genomic landscape of metastatic prostate cancer that has progressed despite castration levels of serum testosterone -as induced by gonadotrophin-releasing hormone agonists (a form of androgen deprivation therapy; ADT), termed castrationresistant prostate cancer (CRPC) -has been even more challenging in light of the lack of biopsy sampling of metastases in routine clinical practice and the difficulties in obtaining quantitatively and qualitatively adequate tissue from metastatic sites, such as bone. Nevertheless, data from multiple rigorous, large, whole-genome, exome and/or transcriptome sequencing studies have revolutionized our understanding of the genomic processes underlying the development and evolution of prostate cancer [3] [4] [5] [6] [7] [8] [9] [10] [11] . For example, we know that DNA copy-number alterations (CNAs) and chromosomal rearrangements, as compared with point mutations or small insertion and/or deletion (indel) mutations, are frequently observed alterations in patients with prostate cancer 3 . Importantly, higher burdens of CNAs and other mutations have been observed in patients with moreaggressive prostate tumours in numerous studies, and correlate with clinical outcomes [3] [4] [5] [6] 10, 12 . Despite these advances, application of these insights into clinical decision making, particularly for patients with metastatic disease, remains in its infancy and therapeutic strategies are largely driven by the presence and the extent of routine clinical and pathological factors. In the future, insights from genomics are likely to have a much more prominent role in drug development, prognostication, patient selection, monitoring treatment response and/or resistance, and clinical practice as a whole. We outline a selected number of important genomic alterations in prostate cancer, and discuss the clinical implications of these discoveries (TABLE 1) . 1 
Molecular subtypes
Findings of gene-expression profiling, exome sequencing and candidate gene-based studies have provided robust evidence supporting the existence of a range of molecular subtypes of prostate cancer, based largely on the presence or absence of gene fusions involving members of the ETS gene family of transcriptional regulators (most commonly ERG, ETV1, ETV4, ETV5 and FLI1). Fusions juxtaposing the noncoding androgen-driven promoter elements of the transmembrane protease gene TMPRSS2 to nearly full length ERG (TMPRSS2-ERG fusions) are the most common ETS gene fusions observed in prostate cancer biopsy samples, occurring in approximately 40-50% of all tumours in PSA-screened, predominantly white populations 3 . Alterations occurring exclusively in the 50-60% of prostate tumours that are ETS fusion-negative (ETS − ) include overexpression of the serine peptidase inhibitor gene SPINK1, recurrent point mutations in the transcriptional repressor gene SPOP, loss and/or mutation of the DNA-binding protein CHD1, and gene fusions or mutations in members of the RAS/RAF family 10, 11, 13, 14 . Data from gene-expression profiling studies support the distinction of ETS fusionpositive (ETS + ) and ETS − tumours; furthermore, findings of several studies [15] [16] [17] , including those from the Cancer Genome Atlas (TCGA) multi-omics profiling study 17 , support the distinction of ETS + tumours into those with ERG fusions (ERG + , comprising approximately 90% of all ETS + tumours) and those with fusions involving non-ERG members of the ETS family (occurring in approximately 5-10% of all ETS + tumours) [15] [16] [17] . Other than TMPRSS2-ERG fusions, the development and progression of most prostate cancers seems to be driven by a variety of diverse, low-frequency oncogenic events. Owing in part to this genetic diversity, research described in TCGA has resulted in a large number of primary prostate cancer molecular classes being described (seven in total). These subtypes are defined by the presence of genetic alterations that are, essentially, mutually exclusive: ERG fusions (46%), ETV1 fusions (8%), ETV4 fusions (4%), FLI1 fusions (1%), SPOP mutations (11%), FOXA1 mutations (3%) and IDH1 mutations (1%) 17 . However, even within these subgroups, marked genetic diversity exists in terms of mutations, copy number alterations, gene expression and DNA methylation, and several common alterations can occur across different molecular classes (for example, chromosome 8q gain or PTEN deletion) 3 . Moreover, 26% of prostate cancers could not be classified into one of these seven subgroups 17 , suggesting that even more genetically distinct molecular subtypes are likely to be uncovered in the future.
Androgen signalling
The androgen receptor Androgen signalling has been the principle focus of medical treatment of prostate cancer since the discovery by Huggins and Hodges that surgical castration of men with advanced-stage prostate cancer resulted in tumour regression 18 . The androgen receptor (AR) signalling axis is the most clinically targeted pathway in patients with both untreated prostate cancer (who are castration-sensitive) and in those with CRPC. Lowering serum testosterone levels, or more specifically, dihydrotestosterone (DHT) levels, activates a feedback loop that increases transcription of the AR in prostate cancer cells 19, 20 . This paradoxical increase in AR expression and signalling is hypothesized to lead to DNA strand breaks, which might be responsible for the resulting AR amplifications seen in 20-55% of CRPC biopsy samples, which is the most common mechanism of developing CRPC 21 
.
In the majority of patients with newly diagnosed CRPC, AR overexpression is driven by these DNA strand breaks, resulting in X-chromosome rearrangement and subsequent focal AR copy number gain 5 . High-level, focal AR amplifications are almost never (in <1% of patients) identified in patients with untreated, localized prostate cancer, but as described above, are much more common in those with CRPC, usually after prolonged exposure to ADT [3] [4] [5] 10, 11, [22] [23] [24] [25] [26] . Mutations in the AR itself are less common than amplifications of the AR and are found in 2-18% of prostate cancer specimens from patients with mCRPC 17 . The resulting overexpression and mutation of the AR has important clinical implications for treatment resistance, and causes promiscuous effects of other adrenal steroids, and even the conversion of first-generation AR antagonists to agonists 27 . Owing to the dependency of prostate cancer on AR signalling, multiple clinical attempts to further suppress AR signalling activity have been made. Most notably, CYP17A1 inhibitors (such as abiraterone) and second-generation anti-androgens (such as enzalutamide) that reduce ligand availability or compete for the ligand-binding domain (LBD) of the AR, respectively, have been developed and shown to confer survival benefits in patients with CRPC [28] [29] [30] [31] [32] . The added benefit derived from the use of second-generation anti-androgens is not only the more complete blockade of the AR compared with first-generation anti-androgens, but also the prevention of nuclear translocation of the AR and the subsequent downstream activation of AR-target genes 33, 34 . Enzalutamide, the first FDA-approved, secondgeneration anti-androgen has demonstrated improvement in overall survival in both the pre-docetaxel and post-docetaxel settings in patients with CRPC, and is currently being tested as a treatment of patients with early-stage prostate cancer 28, 29 . A structurally similar
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A third, structurally distinct, second-generation AR antagonist, ODM-201 has also shown promise in phase I clinical trials as a treatment of both metastatic and nonmetastatic CRPC 36, 37 . Similar to ARN-509, ODM-201, is currently being evaluated in a phase III trial in patients with non-metastatic CRPC (NCT02200614) 38 . Despite widespread clinical use of CYP17A1 inhibitors or second-generation AR antagonists in patients with CRPC, no prospectively validated clinical biomarkers that enable accurate prediction of a response to treatment currently exist. AR amplifications and/or mutations detected in circulating cell-free DNA are associated with resistance to abiraterone and enzalutamide in patients with metastatic CRPC 39 . Additionally, data from transcriptome analysis has revealed that acquired resistance to ARN-509 or enzalutamide correlates with glucocorticoid receptor (GR) upregulation 40 , and high levels of GR expression have been associated with resistance to neoadjuvant androgen deprivation 41 . The effectiveness of combined AR and GR inhibition is being tested in an early phase clinical trial combining enzalutamide with the GR antagonist mifepristone (NCT02012296) 42 . The identification of truncated AR transcript isoforms, referred to as AR splice variants, or AR-Vs is a particularly exciting discovery with high relevance in terms of predicting a response to AR-targeted therapy 43 . These isoforms are missing an LBD, but retain the ability to code for the DNA-binding and transactivation domains. Furthermore, the presence of specific AR-Vs, in comparison to the full-length AR, seems to drive the development of distinct transcriptional profiles in patients with CRPC. For example, AR-V7 has been shown to upregulate a set of cell-cycle genes independent of full-length AR signalling, whereas the full-length AR induces upregulation of gene sets related to biosynthesis, metabolism and secretion that are largely not upregulated by AR-V7 (REF. 44 ). Furthermore, these AR-V splice variants are constitutively active and are not inhibited by standard first-generation or secondgeneration anti-androgens. As such, AR-V expression is associated with progression to CRPC 45, 46 , resistance to anti-androgen therapy 47 , and poor cancer-specific outcomes 48 compared with patients who do not express AR-Vs. For example, the presence of AR-V7 in circulating tumour cells (CTCs) is associated with resistance to abiraterone and enzalutamide, as demonstrated in a small clinical cohort study 47 . These findings have demonstrated that the presence of AR-Vs in CTCs is a potentially powerful biomarker for the identification of patients that are unlikely to respond to therapies that target the full-length AR protein. Assessments of clinical grade assays, performed prospectively in Clinical Laboratory Improvement Amendment-approved laboratories will be of critical importance to determining the predictive validity of AR-V7 detection. Likewise, whether AR-V7 expression is responsible for resistance to AR-targeted therapies, or is an indicator of other processes associated with resistance (for example, AR-V7 expression is often highest in patients with AR amplification) is unclear, and AR-V7 transcripts can be detected at low levels in both benign prostate tissue biopsy specimens, and those from patients with untreated prostate cancer 3 . Following the discovery of AR-Vs that could potentially confer treatment resistance owing to constitutive activity with a lack of a LBD, several new compounds that target other domains of the truncated AR protein have been developed. For instance, compounds that target the N-terminal domain (EPI-001; ESSA Pharma, Vancouver, Canada, ASO EZN-4167; Enzon pharmaceuticals, Florida, USA) and the DNA-binding domain (ISIS-ARRx, Ionis pharmaceuticals, California, USA) of the AR have demonstrated early potential as viable thera pies in preclinical models [49] [50] [51] [52] [53] and in a phase I clini cal trial 52 . These experimental therapies will need to demonstrate an acceptable level of specificity for the AR, with few, or no off-target effects; however, tremendous hope exists that these therapies could provide clinical benefits for patients whose tumours are no longer reliant on the LBD of the AR and are resistant to antiandrogen therapy. Likewise, AR-directed therapies with combined mechanisms of action might enable targeting of both the full-length AR and AR-Vs. For example, based on data demonstrating efficacy in a small number of patients with AR-V7 expression in CTCs, a phase III randomized trial (NCT02438007) 54 has been initiated to test galeterone -a CYP17A1 inhibitor that also acts as a direct AR antagonist and degrades full-length and truncated AR compared with enzalutamide in men with CRPC and AR-V7 expression, as confirmed by analysis of CTCs. Importantly, this trial is the first phase III trial in patients with prostate cancer to use the presence of a molecular biomarker as an inclusion criterion.
AR cofactors
A host of cofactors modulate the expression of downstream targets of the AR 55, 56 . These include, but are not limited to, the forkhead protein FOXA1, the transcription factor GATA2, and the P160 steroid receptor co-activator proteins, NCoA-1, NCoA-2 and NCoA-3. Unlike AR mutations that are almost exclusively found in CRPC biopsy samples, mutations of these AR cofactors have been detected in both primary and metastatic tumours 3, 5, 11 . When combining AR alterations and AR cofactor aberrations, 71% of patients with CRPC harbour AR signalling pathway aberrations 3 . FOXA1 interacts with the AR and serves as a pioneer cofactor that is capable of specifying unique AR binding sites 57 . Additionally, FOXA1 is also able to a regulate metastatic potential in an AR-independent manner 58 , thus development of an inhibitor of FOXA1 might hold some promise 59 . GATA2 colocalizes with FOXA1 and the AR on chromatin, and a complex feedback mechanism exists between AR and GATA2 whereby GATA2 promotes expression of AR and, conversely, GATA2 expression is repressed by androgens signalling via the AR 60 . Furthermore, preclinical data support the efficacy of bromodomain and extra-terminal motif (BET) protein inhibitors, which have been shown to downregulate AR by disrupting the AR-bromodomain-containing protein 4 interaction at the N-terminal domain of the AR, thus altering gene expression by preventing interactions of this complex with chromatin 61 . These results have led to the clinical assessment of BET inhibitors as a treatment of CRPC, including a phase I trial of the BET inhibitor OTX015 (Merck, New Jersey, USA) in men with CRPC, among patients with other solid tumours (NCT02259114) 62 . The P160 SRC family genes, NCOA1, NCOA2 and NCOA3 that function as steroid receptor co-activators, are recognized as important cofactors in CRPC. Even in the absence of circulating androgens, overexpression of NCoA-1 or NCoA-2 can drive increased AR transactivation 63 . NCoA-2 is amplified in approximately 6% of patients with advanced-stage prostate cancer, and increased NCoA-2 function amplifies AR pathway activity 10, 64 . NCoA-3 overexpression is associated with tumour proliferation in patients with prostate cancer, and notably, is a key target of the ubiquitin ligase SPOP 11, 65 . Targeting these P160 SRC proteins might prove a beneficial treatment of CRPC and might resensitize patients to the standard treatments of CRPC. Promisingly, 65% of patients with metastatic CRPC have a genetic aberration that is potentially targetable through use of established agents, even excluding those with alterations of the AR signalling axis 3 .
TMPRSS2-ETS fusions
Stimulation of the AR can bring the TMPRSS2 and the ERG gene loci into close proximity, an effect thought to be critical for the development of the TMRPSS-ERG gene fusion [66] [67] [68] . Younger men (around 55% of those aged <50 years) have higher incidences of structural rearrangements and ERG gene fusions than older men (around 35% of those aged >75 years), resulting in the hypothesis that androgen-activated transcription might be an early driver of prostate cancer 69 . The translational relevance of TMPRSS2-ERG fusions has been demonstrated by the introduction of a urine-based early detection test (in combination with urine levels of PCA3, which is a noncoding RNA transcript) and a diagnostic, tissue-based test (using antibodies directed against ERG) [70] [71] [72] [73] . Thus, the first clini cal applications of ETS fusions are as diagnostic tools, exploiting the specificity of this gene fusion to promote prostate cancer, rather than as a prognostic biomarker post-treatment. The prognostic utility of ERG fusions has been extensively investigated in various contexts, particularly after radical prostatectomy, with the lar gest published series indicating no utility of the presence of these fusions or ERG overexpression for prediction of biochemical recurrence 74, 75 . No clinically available methods of directly inhibiting TMPRSS2-ERG signalling currently exist; although, inducible knockdown of ERG, which is endogenously expressed in the VCaP CRPC cell line has shown that ERG drives cellular proliferation and blocks differentiation of these cells to neuroendocrine or luminal cell types, supporting the clinical utility of targeting these early, driving alterations 76 . Likewise, in preclinical studies investigating targeted deletion of TMPRSS2, this protein was found to promote cancer cell invasion and metastasis 77 . Inhibition of ETS cofactors, rather than the fusion product itself, has attracted increased interest as a potential therapeutic strategy. In preclinical studies, ETSpositive tumours have been shown to be more sensitive to pharmacological inhibition of targetable cofactors, including PARP1, HDAC1, and DNAPK 74, 78 . Multiple phase I and II studies have focused on the inhibition of PARP1 in patients with CRPC, most notably a randomized study, in which patients were stratified based on ETS fusion status (NCT01576172) 79 . Two phase II studies designed to investigate the effectiveness of HDAC inhibitors in patients with CRPC have yielded disappointing results 80, 81 
Signal transduction pathways
Molecularly targeted therapies for the treatment of prostate cancer have identified the importance and ubiquity of androgen axis signalling in the pathogenesis of this malignancy, largely focused on androgen signalling pathways. Nevertheless, the importance of other signal transduction cascades has been increasingly elucidated from the findings of genomic analyses. For example, in the setting of metastatic CRPC, nearly 50% of tumours harbour PI3K abnormalities, and 18% have MAPK or WNT alterations 3 . Furthermore, 100% and 90% of meta static tumours have upregulated PI3K and MAPK signalling, respectively, according to gene-expression analyses 10 .
PI3K pathway
Other than the androgen signalling axis, the PI3K signalling cascade is the most commonly dysregulated signal transduction pathway in patients with prostate cancer. The PI3K pathway is a critical regulator of proliferation, survival, metabolism, angiogenesis, and immune function. Hyperactivation of the pathway through loss of PTEN, which encodes a lipid phosphatase that acts as a negative regulator of PI3K signalling is by far the most common PI3K aberration observed in patients with prostate cancer 3, 10 . Homozygous PTEN deletions were present in 15% of primary prostate cancers in the TCGA dataset, which is one of the highest incidences of this deletion among any tumour type, and PTEN mutations were present in another 2% 17 . PTEN alterations are even more common in the setting of metastatic disease, with over 40% of tumours having PTEN mutation or loss 3, 5, 10, 17 . PTEN loss has been associated with a poor clinical outcome in numerous studies compared with patients whose tumours express wild-type PTEN [85] [86] [87] [88] [89] , with some 88 , but not all studies 89 , indicating that the prognostic value of PTEN loss is dependent on ERG-fusion status. PI3K signalling and androgen signalling have been suggested to be reciprocally regu lated 90 , and treatment with combination therapy is likely to be necessary to overcome intrinsic and acquired resistance to single-agent therapy, given the findings of trials designed to investigate the efficacy of pan-PI3K or dual PI3K-mTOR inhibitors have been disappointing to date 91, 92 .
Wnt pathway
Alterations in the Wnt signalling pathway are also common in prostate cancer, both in the primary setting and in patients with metastatic CRPC, where it is present in approximately 18% of patients 3, 5, 17 . Canonical Wnt signalling is an evolutionarily conserved pathway that has been implicated in cancer stem-cell maintenance, epithelial-to-mesenchymal transition, embryonic development and homeostasis in adults 93 . Alterations have been observed in multiple nodes of the Wnt-signalling pathway in patients with prostate cancer, including recurrent mutations in CTNNB1, the gene encoding the central mediator of the Wnt pathway, β-catenin 3, 17 , and APC, which forms part of the multiprotein complex that regulates β-catenin levels 3, 5, 94 . Furthermore, mutations in the ubiquitin ligases RNF43, ZNRF3, and in RSPO2, an activator of Wnt signalling via activation of the G-protein coupled receptors LGR 4, 5 or 6 was observed in 6% of patients with mCRPC 3 . The presence of mutations in these genes in patients with metastatic CRPC was mutually exclusive of APC alterations 3 
MAPK pathway
The MAPK/ERK pathway, which is implicated in cell survival, cell-cycle progression, tumour dissemination, and resistance to therapy in multiple cancers 110 , also seems to have a role in a subset of prostate cancers, and data from preclinical research suggests an association with more-aggressive disease in certain genetic contexts 111 . BRAF is the most commonly altered MAPK gene in prostate cancer, with gene fusions or activating mutations present in 2-3% of tumours 3, 5, 17 . Interestingly, canonical BRAF V600E mutation was not observed in prostate cancer specimens analysed in the TCGA dataset, although this mutation has been described, rarely, in other studies 10, 17 . Additionally, no activating BRAF rearrange ments were found in the TCGA study 17 , despite these having been described previously in prostate cancer 112 . Given the rarity of BRAF V600E mutations in prostate cancer, less specific BRAF or MEK inhibitors might prove to have more clinical utility in patients with prostate cancer than the currently available mutant BRAF inhibitors, such as vemurafenib.
IDH1 signalling
Approximately 1% of primary prostate cancers are defined by the presence of isocitrate dehydrogenase 1 (IDH1) Arg132His hotspot mutations 17 . This critical finding from the TCGA prostate cancer study represents a novel prostate cancer molecular subtype and confirms previous observations of these mutations in prostate cancer 94, [113] [114] [115] . These IDH1 gene mutations generally result in a loss of function, owing to the conversion of isocitrate to 2-ketoglutarate. Instead, the altered enzyme adopts an abnormal function: production of D-2-hydroxyglutarate 116 . These genetic changes have been found to inhibit the enzymatic function of many α-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases, resulting in widespread changes in the epigenome.
The presence of these IDH1 mutations defines a rare, unique subset of early onset prostate cancer, with relatively few copy number alterations and even higher levels of genomic hypermethylation compared with IDH1-mutant glioblastoma or acute myelocytic leukaemia (AML) 117, 118 . Notably, in patients with either AML or glioblastoma, those with IDH1 mutations have a markedly better prognosis than those with wildtype IDH1 (REFS 119,120) . Whether or not the presence of IDH1 mutations also portends an improved prognosis for patients with prostate cancer is worthy of future investigation, given the significant potential implications for active surveillance and treatment recommendations in men harbouring tumours with this alteration. Additionally, patients with IDH1 mutations might be candidates for treatment with one of the various IDH1-specific therapies that are currently being developed 120, 121 .
Cell cycle and/or proliferation
Similar to many other cancers, alterations in genes encoding proteins involved in regulation of the cell cycle have an important role in prostate cancer. For example, TP53 is mutated or deleted in 8% of primary prostate cancers and up to 53% of metastatic CRPCs 3, 5, 10, 17, 94 . TP53 encodes the p53 transcription factor that, in response to DNA damage, activates the G1-S cell-cycle checkpoint and the apoptotic signalling cascade 122 . Furthermore, other genes encoding important inhibitors of cell-cycle progression at G1-S, including CDKN2A, CDKN2B and CDKN1B, are each lost in about 2-3% of primary prostate cancers 17 . RB1, another critical negative regulator of the G1-S checkpoint that is responsible for repressing the E2F family of transcription factors 123 , is also commonly lost in metastatic CRPC 3, 10, 94 (most specifically in small-cell carcinoma); whereas CCND1, the gene encoding cyclin D1, which is an activator of cell-cycle progression through G1-S transition, is amplified in recurrent disease 3, 94 . Thus, dysfunction of the G1-S checkpoint, owing to a variety of different genetic aetiologies, is a frequently occurring molecular event in patients with prostate cancer, particularly in those with metastatic CRPC.
Despite being perhaps the most commonly altered set of genes across all cancers, clinical therapeutic strategies targeting cancer cells harbouring deficiencies in cellcycle regulation (besides non-selective chemo therapy) have been lacking. However, multiple new agents are entering the clinic and have shown promising results in the metastatic setting. For example, the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib, in combination with anti-oestrogen therapy, has demonstrated impressive activity in patients with hormone-receptor positive breast cancer 124, 125 . CDK4/6 inhibitors are expected to be particularly effective in tumours harbouring inactivating CDKN2A/B mutations or CCND1 amplification, both of which are recurrent alterations present in primary and, more commonly, metastatic CRPC. Three registered clinical trials are investigating the effectiveness of these agents in patients with prostate cancer: ribociclib in combination with docetaxel in patients with metastatic CRPC (NCT02494921) 126 , enzalutamide with or without ribo ciclib in patients with metastatic CRPC (NCT02555189) 127 , and ADT with or without paclociclib in patients with hormone-sensitive prostate cancer (NCT02059213) 128 , in which patients with RB1 wild-type tumours were pre-selected for recruitment. This latter trial is the first example of biomarker-driven recruitment of patients with hormone-sensitive prostate cancer.
Targeting cells with p53 deficiency has long been a goal of oncologists, but has proven difficult in clinical practice 129 . Given that p53 is a fundamental regulator of the G1-S checkpoint, one strategy for targeting cells with this deficiency could be to exploit their hypothesized increased reliance on the G2-M checkpoint for DNA damage repair. Inhibitors of the G2-M regulatory proteins ATR 130, 131 , Wee1 (REFS 132, 133) and Chk1 (REFS 134, 135) have increased activity when used as single agents, and also promote sensitization of p53-deficient cancer cells to DNA-damaging agents. Inhibitors of each of these molecules have entered early phase clinical testing in various cancer types 136, 137 (NCT02223923) 138 and might be effective in patients with metastatic CRPC.
In addition to G1-S checkpoint aberrations, localized prostate cancers might also harbour amplification of one of the three MYC isoforms that also promote progression from G 1 -S phase: MYC (also known as c-MYC), MYCL, or MYCN 8, 17 . Like p53, MYC has long been considered undruggable, and direct targeting is challenging with standard pharmaceutical approaches 139 . Nevertheless, in a novel approach to this challenge, DCR-MYC, a first-in-class Dicer substrate small, interfering doublestranded RNA targeted to the MYC oncogene in a lipid nanoparticle suspension is currently being tested in early phase clinical trials (NCT02110563 (REF. DNA damage repair/heredity DNA repair. The DNA damage repair (DDR) response is governed by input from a diverse array of signalling cascades that are integral to the maintenance of genomic integrity 148 . Many proteins involved in DDR act as tumour suppressors, thus preventing the formation and propagation of both mutations and copy-number alterations. Genomic instability via loss of DDR proteins is common in prostate cancers compared with many other types of cancer, owing to both somatic and germline alterations. For example, approximately 19% of primary prostate cancers and 23% of patients with mCRPC harbour inactivating mutations in DDR genes 3, 5, 17, 94 . Notably, certain DDR deficiencies seem more common in patients with metastatic CRPC than in those with primary prostate cancer. For example, approximately 20% of metastatic CRPC primary tumour samples have been reported to harbour germline and/or somatic aberrations in BRCA2, BRCA1, or ATM 3, 5, 94, 149 , whereas only ~3% of tumours from those with primary prostate cancer had germline or somatic alterations in BRCA1 and BRCA2 (REF. 17) .
Losses or mutations of BRCA2, ATM, and BRCA1 are the most commonly reported mutations in DDR genes in patients with prostate cancer 3, 5, 17, 94 . The wildtype forms of these genes are important components of homologous recombination, a high fidelity DDR process that utilizes the sister chromatid as a template during G2/M to excise and replace defective stretches of DNA in an error-free manner. Mutations in other components of the homologous recombination response have also been described, including those in PALB2, RAD51B and RAD51C 3, 17 . Thus, defective homologous recombination is a recurrent motif in the development of prostate cancer, particularly in the advanced-stage or castration-resistant setting. Furthermore, data from a large pan-cancer analysis revealed a mutational signature correlating with mismatch repair deficiency in a subset of prostate cancers 150 , and loss-of-function genomic lesions in mismatch repair proteins (most frequently somatic mutations and deletions in MSH2) have been described in several datasets 3, 5, [151] [152] [153] . Given the high mutation load of their tumours, patients that have prostate cancer with mismatch repair deficiencies might be good candidates for investigation of immunotherapeutic approaches, such as cytotoxic T-lymphocyte protein 4 or programmed cell-death 1 inhibition 154, 155 . Currently, defective or lost DDR proteins cannot be directly targeted pharmacologically; although, these aberrations might create tumour-specific vulnerabilities that can be exploited via the principal of synthetic lethality. This process occurs when two cellular pathways are inhibited simultaneously, resulting in cell death, but inhibition of either pathway by itself is not lethal. When DNA repair function is intact, single-strand DNA breaks are repaired through the base-excision-repair pathway. Poly(ADP-ribose) polymerase (PARP) is a key component of the base-excision-repair pathway, and inhibition of this protein results in an increased frequency of single-strand DNA breaks and eventually the creation of double-strand DNA breaks during replication. Normally, these double-strand breaks are repaired by homologous recombination. However, if cells have mutations in genes that encode proteins that control homologous recombination (such as BRCA) then DNA replication is likely to fail. The combination of PARP inhibition in the presence of BRCA mutations impairs these two damage repair pathways, causing selective synthetic lethality 156 . The clinical relevance of synthetic lethality was originally demonstrated by the discovery that breast and ovarian cancers with BRCA deficiencies are exquisitely sensitive to PARP inhibition [157] [158] [159] . These findings might have relevance for prostate cancer. Data from a phase II trial with a cohort that contained eight patients with germline BRCA1 or BRCA2 mutations and recurrent cancer demonstrated that half of these patients with advanced-stage prostate cancer had responses 160 . Even more promisingly, following the TOPARP-A trial, investigators reported that 14 of 16 (87.5%) patients with mCRPC and homozygous deletions or deleterious mutations in DNA-damage repair genes, such as BRCA1 or BRCA2, ATM, CHEK2, FANCA and PALB2 responded to olaparib, in comparison to two of 33 (6%) without these aberrations 161 . This high level of specificity of genomic alterations to a targeted therapy is unprecedented in patients with prostate cancer. Serious (grade ≥3) treatment-related adverse events included anaemia (in 10 patients), fatigue (in six patients), leukopenia (in three patients), thrombocytopenia (in two patients) and neutropenia (in two patients). Multiple other trials in the past 5 years designed to investigate the effectiveness of PARP inhibitors in patients with prostate cancer are currently underway or have been completed (NCT01576172 (REF. 79) and a complete response in a patient with deficiencies in DDR genes who was treated with a PARP inhibitor (with or without other therapies) has also been described 164 .
In addition to predicting a response to targeted DDR inhibition, tumours with genomic deficiencies in homologous recombination or Fanconi anaemia proteins might also be more responsive to platinum-based chemotherapy 165, 166 . Platinum-based chemotherapy is rarely used in patients with prostate cancer (except in those with small-cell or neuroendocrine carcinoma) given the lack of benefit derived from this treatment in unselected patients. However, this might be a promising approach for patients with mCRPC harbouring genetic DDR pathway alterations; thus, an evaluation of the effectiveness of PARP inhibitors compared with that of chemotherapy might be warranted.
The existence of a novel interplay between DNA repair and AR signalling was described in 2013 (REF. 167 ). Inhibition of the AR seems to suppress non-homologous end joining, and to reduce the functional ability of the DNA-dependent protein kinase catalytic subunit 168 . Furthermore, genotoxic stress (such as radiotherapy) not only causes DNA damage, but also upregulates AR signalling and pro-survival pathways to mediate treatment resistance 169 . Further research is ongoing to better characterize how to utilize this information to enable the rational combination of radiotherapy with ADT (NCT02297386) 170 . Additionally, an important interplay exists between PARP and the AR given that PARP-1 is recruited to sites of AR function and supports AR transcriptional function, suggesting that PARP should be further investigated as a treatment target in patients with prostate cancer 167, 168 . Heredity. Data from genomic studies have confirmed that, in addition to the somatic mutations present in prostate cancer, germline aberrations in DDR genes also have a critical effect on genetic predisposition to prostate cancer 3, 171 . BRCA2 was one of the first mutated genes to be associated with an increased risk of prostate cancer [172] [173] [174] . Furthermore, the presence of BRCA1 mutations also increases the risk of prostate cancer, albeit to a lesser extent than the presence of BRCA2 aberrations 175 . Additionally, men with germline mutations in mismatch repair genes have approximately twice the risk of developing prostate cancer as unaffected individuals, with a cumulative risk of approximately 30% by the age of 80, compared with around 18% in the age-matched general population 176 . Other genetic alterations have been identi fied that confer an increased familial risk of prostate cancer (such as HOXB13 mutations), however, these mutations usually occur at low frequencies 177 .
Identifying men who have a strong genetic predisposition to prostate cancer has important clinical implications. For example, these men might be eligible for more intense screening, or lowering the serum PSA threshold that indicates a need for biopsy sampling. Unfortunately, no reliable evidence exists that pharmacological prevention, such as the use of finasteride, selenium, and/or vitamins can prevent, or reduce the risk of developing high-grade prostate cancers 178, 179 . Thus, no pharmacological strategy for prostate cancer prevention can currently be recommended. The role of more-aggressive risk reduction, such as prophylactic prostatectomy, is also unclear. Further study of screening and prevention of prostate cancer in men with a high genetic predisposition to prostate cancer is an important avenue for future investigation.
Tumour heterogeneity and evolution
The substantial interpatient tumour heterogeneity observed among patients with prostate cancer is highlighted by the variety of different molecular aberrations present across different cancers 3,10 (FIGURE 1). This interpatient heterogeneity has been a major challenge in identifying effective therapies in 'all-comers' in randomized trials, given that the potential benefit derived from use of a targeted treatment in selected patients harbouring a predictive genomic alteration might be masked if the alteration is only present in a small subset of those enrolled. Nevertheless, intrapatient heterogeneity might also pose hurdles to the personalization of treatment. In patients with localized prostate cancer, the majority of prostate cancers are known to be multifocal 180, 181 . Furthermore, although these multifocal tumours have often been identified to be genetically distinct, suggesting an independent origin, non-driving somatic mutations might be shared between tumour foci and even among histologically 'normal' prostate tissue samples 7, 8, 182 . Moreover, lethal metastases have been reported to arise from a minor population of subclones, including dissemination from an organ-confined, lowgrade area of a bulky, high-grade primary tumour 183 . Likewise, data from sequential profiling of circulating cell-free DNA has demonstrated that the basic prostate cancer molecular subtype (defined by ERG-fusion status) might change in response to selective pressure induced by anti-androgen therapy 184 . Therefore, the use of targeted biopsy sampling using image-guided techniques (CT, MRI, and/or ultrasonography), both in patients with localized, and metastatic CRPC will need to be carefully evaluated to determine whether or not this approach can capture the dominant biology of any one patient's cancer. Additionally, the delivery of focal therapy to the prostate gland, such as focal brachytherapy or cryotherapy, might be unwise until a method to readily detect the driver foci that are responsible for metastatic spread is developed.
Given the extensive intratumoural and intertumoural heterogeneity observed in patients with prostate cancer, in line with Darwinian theories of evolution, certain subclones containing a selective growth or survival advantage in comparison to others are likely to proliferate and form the majority of the tumour population throughout the natural history of the disease, and in response to selective pressures 6, 8, 185 . Eventually, in most patients with lethal prostate cancer, a subset of tumour subclones gains the ability to disseminate to distant organs. Furthermore, the introduction of therapeutic interventions, which provide new pressures on tumour selection, can radically reshape the subclonal composition of a tumour 184 . Thus, the tumour genome and epigenome are in a dynamic state of selection pressure and evolutionary drift as the tumour continually divides and new mutations arise.
Some of the most interesting insights to emerge from genome sequencing projects involve tracking the evolution of prostate cancer from a locally invasive process into a disseminated malignancy. For example, data from several copy-number analyses and genome-sequencing studies from individual patients have suggested that, despite the multifocal and multiclonal nature of primary prostate cancers, lethal metastases might arise from a single subclone 183, 186 . However, studies published in the past 2 years, with data from multiple patients, suggest that prostate cancer metastases can arise from either a single, or several subclones within the primary tumour 6, 184 . Furthermore, the complexity of patterns of metastatic spread of prostate cancer has been highlighted by the findings of genomic studies 6, 187, 188 . In addition to the classic primary-to-metastasis model, high rates of metastasis-to-metastasis, and even metastasisto-surgical bed, spread have been observed in heavily treated patients 6, 187 . In summary, these data support the hypothesis that, rather than only unidirectional seeding from the primary to metastatic sites, metastatic CRPC is truly a systemic disease arising from a subclone or subclones with multidirectional spread of subclones between all sites of malignancy 188 . This hypothesis has clinical implications for treating both the primary, as well as metastatic sites in order to limit the extent of any further metastatic progression. Given that not all metastatic spread arises from the primary tumour, ablation of oligometastases in patients in whom the primary tumour is eradicated might, in theory, decrease the reservoir of subclones containing the ability to disseminate, thereby slowing the progression of metastatic spread.
Multiple lines of evidence suggest that tumours evolve in response to treatment 184, 187 . For example, certain aberrations such as AR mutations and amplifications that are common in prostate biopsy samples from patients with mCRPC are almost never detected in similar samples from patients with hormone-naive prostate cancer 3, 5, 6, 189 . Additionally, the relative proportions of circulating DNA from the various tumour subclones markedly changes over time in response to treatment, with those containing mutations that are known to confer treatment resistance emerging during progression, whereas others regress during treatment responses, thus revealing a complex dynamic of temporal and spatial hetero geneity 184 . In many cases these resistant clones are already extant in small numbers before treatment, rather than arising de novo, and eventually become the dominant population under selection pressure. For example, in the TCGA study, researchers detected AR splice variants, including the AR-V7 splice variant that is associated with resistance to anti-androgen therapy, and is present at low levels in biopsy samples from normal prostate tissue and from androgen-naive prostate cancers 17 . Given that diversity often exists with respect to therapeutic resistance mechanisms across different metastatic sites, a challenge can occur when a targeted therapy is adequately controlling the majority of the patient's disease, but one or more foci are discordantly progressing. One potential method that is of clinical interest, but needs to be rigorously tested in the context of clinical trials, is to maintain patients on targeted thera pies while also controlling the emergence of metastatic tumour clones that harbour acquired resistance using ablative treatments. Stereotactic body radiotherapy (SBRT) is one form of ablative therapy that allows high doses of radiotherapy to be delivered to the tumour and avoids exposing normal tissue to radiation. This technique holds promise for the treatment of patients in the metastatic setting, which should be tested prospectively.
The dynamic intratumoural heterogeneity observed in patients with prostate cancer, along with its fundamental intertumoural diversity, is a major challenge to the personalized management of patients with this disease. Of particular relevance, targeting early driving 'truncal' alterations in prostate cancer, such as ERG gene fusions or SPOP mutations, is currently not possible. Given the assumption that prostate cancer metastases might arise from a minor subclonal population, attempts to utilize molecular sequencing to improve prognostication will be extremely challenging. Hence, determining both common and rare patterns of tumour progression is a critical area of research for clinicians treating patients with prostate cancer. Such studies, which must track the emergence of lethal clones from the primary tumour to ADT-refractory CRPC, through to disease that is refractory to second-line anti-androgen therapies, are complicated by the long follow-up duration that is required to obtain such samples. Likewise, studies assessing tumour tissue histology, circulating tumour cells and cell-free DNA are required to determine the most informative (and clinically relevant) approaches.
The molecular diversity of metastatic prostate cancer generally indicates that achieving long-term remission from treatment with agents targeted to a single pathway is unlikely, and the clinical effectiveness of combination strategies, possibly using orthogonal targets or synergistic combinations, should be investigated 185 . In addition, the dynamic nature of prostate cancer genomics supports the repeated, longitudinal evaluation of the genomic charac teristics of a patient's tumour over time, and during treatment 184 . For example, all rapid autopsy studies conducted on heavily treated patients with mCRPC before the second-generation antiandrogen therapy era demonstrate uniform ETS fusion status within an individual patient's metastases 5, 6, 186, 190 , and assessment of cell-free DNA supports dynamic ETS fusion status upon treatment with second-generation anti-androgens 184 . Hence, non-invasive methods (coupled with tissue-based assessments) are being actively investigated in order to capture the spectrum of a patient's tumour heterogeneity in response to treatment in real-time through assessment of circulating tumour cells, cell-free DNA, urine and serum biomarkers, and molecular imaging.
Neuroendocrine prostate cancer Small-cell carcinoma of the prostate can exist de novo within the prostate and patients with this type of prostate cancer typically have a shorter overall survival compared with those who have prostate adenocarcinoma 191 . Additionally, prostate adenocarcinomas can also progress and lose expression of active AR signalling markers (such as serum PSA) with, or without small-cell carcinoma differentiation, thus likely reflecting a truly AR-independent phenotype and a terminally differentiated state 3, 5, 152, 192 .
Clinically, patients with this type of prostate cancer have metastases in atypical visceral sites, and abnormally low serum PSA levels 149, [192] [193] [194] . The terminology of neuroendocrine prostate cancer (NEPC) is evolving and this type of prostate cancer is clearly a heterogeneous spectrum of de-differentiation, particularly as patients are increasingly being treated with therapies designed to target androgen signalling 149, 192, 195 . The exact incidence of NEPC is unclear, and ranges from 1-32% after treatment with enzalutamide or abiraterone 3, 196 . Distinct genomic alterations are likely required to enable prostate cancer to transition from an AR-dependent adenocarcinoma to an AR-independent disease state (with or without overt neuroendocrine differentiation, as defined by marker expression). Some of the proposed and identified aberrations include loss of TP53 and RB1, and gain of AURKA, MYCN, MYCL and PEG10, a gene that encodes an anti-apoptotic signalling protein 94, 149, 192, [197] [198] [199] [200] . Co-amplification of the genes AURKA and MYCN, although not consistently observed, has been reported in up to 40% of patients with NEPC 192 . Based on these findings, a phase II trial of an AURKA inhibitor MLN8237 in patients with NEPC (NCT01799278) 201 is underway. With the continued understanding of neuroendocrine/small-cell prostate cancer, and the process of de-differentiation, the current list of target genes (such as MYCN, AURKA and PEG10) will likely expand. Owing to a lack of functional reliance on AR signalling, typical AR-based therapies are largely ineffective in patients who exclusively harbour these aggressive disease variants, and novel treatments are desperately needed.
Conclusions
Improvements in multiplatform sequencing technologies have revolutionized research into prostate cancer genetics, enabling unprecedented insight into the biology of this disease. This knowledge has elucidated promising opportunities for personalized treatment interventions, and has also highlighted the formidable hurdles in managing a dynamically evolving heterogeneous disease. Developing novel avenues for applying this knowledge regarding genomics, to the clinical care of patients with prostate cancer in order to increase thera peutic effectiveness, while limiting adverse treatment sequelae, is a major challenge to clinical oncology over the coming years. To overcome these hurdles, continued multidisciplinary integration of basic science, genomics, bioinformatics, industry research and clinical practice will be necessary in order to advance the clinical science of prostate cancer.
